NDAINJECTIONINJECTABLE
Approved
Nov 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ACHROMYCIN (tetracycline hydrochloride) by Pfizer is clinical pharmacology tetracyclines are readily absorbed and are bound to plasma protein in varying degrees. Approved for bacterial vaginosis, vulvovaginal candidiasis. First approved in 1953.
Drug data last refreshed 21h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Tetracyclines are readily absorbed and are bound to plasma protein in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Microbiology Tetracyclines are primarily…
Indications (2)
Worked on ACHROMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.